JP2023514784A - 放射性金属用キレート剤組成物およびその使用方法 - Google Patents

放射性金属用キレート剤組成物およびその使用方法 Download PDF

Info

Publication number
JP2023514784A
JP2023514784A JP2022550888A JP2022550888A JP2023514784A JP 2023514784 A JP2023514784 A JP 2023514784A JP 2022550888 A JP2022550888 A JP 2022550888A JP 2022550888 A JP2022550888 A JP 2022550888A JP 2023514784 A JP2023514784 A JP 2023514784A
Authority
JP
Japan
Prior art keywords
vivo
radioisotope
peptide
crown
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514784A5 (enExample
Inventor
ヤン、フア
ガオ、フォン
シェーファー、ポール
ユアン、ジェリャン
チャン、チェンチェン
ベナール、フランソワ
ウォートン、ルーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provincial Health Services Authority
Original Assignee
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provincial Health Services Authority filed Critical Provincial Health Services Authority
Publication of JP2023514784A publication Critical patent/JP2023514784A/ja
Publication of JP2023514784A5 publication Critical patent/JP2023514784A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/086—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being alphaMSH, alpha melanocyte stimulating hormone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Peptides Or Proteins (AREA)
JP2022550888A 2020-02-25 2021-02-25 放射性金属用キレート剤組成物およびその使用方法 Pending JP2023514784A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062981113P 2020-02-25 2020-02-25
US62/981,113 2020-02-25
US202062993636P 2020-03-23 2020-03-23
US62/993,636 2020-03-23
PCT/CA2021/050226 WO2021168567A1 (en) 2020-02-25 2021-02-25 Chelator compositions for radiometals and methods of using same

Publications (2)

Publication Number Publication Date
JP2023514784A true JP2023514784A (ja) 2023-04-10
JP2023514784A5 JP2023514784A5 (enExample) 2024-03-05

Family

ID=77490568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550888A Pending JP2023514784A (ja) 2020-02-25 2021-02-25 放射性金属用キレート剤組成物およびその使用方法

Country Status (7)

Country Link
US (1) US20230270892A1 (enExample)
EP (1) EP4110768A4 (enExample)
JP (1) JP2023514784A (enExample)
AU (1) AU2021226147A1 (enExample)
CA (1) CA3172811A1 (enExample)
WO (1) WO2021168567A1 (enExample)
ZA (1) ZA202210224B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
CA3136979A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
WO2022082312A1 (en) 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
CN114807636B (zh) * 2021-12-31 2023-10-20 中国工程物理研究院核物理与化学研究所 一种无载体177Lu和161Tb的GMP生产方法
KR20240167790A (ko) * 2022-03-30 2024-11-28 니혼 메디피직스 가부시키가이샤 복합체의 제조 방법
CN119325393A (zh) * 2022-05-03 2025-01-17 北卡罗来纳大学教堂山分校 用于成像和治疗应用的靶向ntsr的试剂的开发
CN115286697B (zh) * 2022-09-29 2022-12-13 烟台蓝纳成生物技术有限公司 一种双重靶向化合物及其制备方法和应用
WO2024235273A1 (zh) * 2023-05-15 2024-11-21 成都社泰医疗科技有限公司 多靶向化合物及其应用
AU2024346916A1 (en) * 2023-09-22 2026-03-26 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
WO2025156030A1 (en) * 2024-01-25 2025-07-31 The University Of British Columbia 1,7,13-trioxa-4,10,16-triazacyclooctadecane chelator compositions for radiometals and methods of using same
WO2025171492A1 (en) * 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
WO2025194281A1 (en) * 2024-03-22 2025-09-25 Triumf Inc. Chelator compositions for radiometals and methods of using same
CN118725025A (zh) * 2024-06-04 2024-10-01 厦门稀土材料研究所 用于177Lu标记的三齿类酰胺酸型双功能螯合剂及其制备方法和应用
WO2026000067A1 (en) * 2024-06-24 2026-01-02 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
WO2026096892A1 (en) * 2024-11-01 2026-05-07 Ratio Therapeutics, Inc. Somatostatin binding compositions and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098149A1 (en) * 2001-01-09 2002-07-25 Shuang Liu New macrocyclic chelants useful for metallopharmaceuticals
CN104151368A (zh) * 2014-08-06 2014-11-19 北京师范大学 一种稀土铕配合物及其合成方法
CN104151367A (zh) * 2014-08-06 2014-11-19 北京师范大学 一种稀土镧配合物及其合成方法
WO2019222851A1 (en) * 2018-05-23 2019-11-28 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102212042A (zh) * 2011-04-18 2011-10-12 北京师范大学 一种四氮杂冠醚的合成方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098149A1 (en) * 2001-01-09 2002-07-25 Shuang Liu New macrocyclic chelants useful for metallopharmaceuticals
CN104151368A (zh) * 2014-08-06 2014-11-19 北京师范大学 一种稀土铕配合物及其合成方法
CN104151367A (zh) * 2014-08-06 2014-11-19 北京师范大学 一种稀土镧配合物及其合成方法
WO2019222851A1 (en) * 2018-05-23 2019-11-28 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy

Also Published As

Publication number Publication date
US20230270892A1 (en) 2023-08-31
ZA202210224B (en) 2023-04-26
AU2021226147A1 (en) 2022-09-22
CA3172811A1 (en) 2021-09-02
EP4110768A1 (en) 2023-01-04
WO2021168567A1 (en) 2021-09-02
EP4110768A4 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
US20230270892A1 (en) Chelator compositions for radiometals and methods of using same
Benesova et al. Albumin-binding PSMA ligands: optimization of the tissue distribution profile
ES2953196T3 (es) Radiotrazador de modo dual de unión a PSMA y terapéutico
US20210393809A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
US12527885B2 (en) High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
RS66467B1 (sr) Kompleks koji se sastoji iz jedinjenja koje cilja psma vezano sa radionuklidom olova ili torijuma
EP3417883A1 (en) Targeted alpha-particle emitting complexes comprising thorium radionuclide and hydroxypyridinone containing ligand
Tsuchihashi et al. Development of novel 111In/225Ac-labeled agent targeting PSMA for highly efficient cancer radiotheranostics
Zha et al. New PSMA-targeting ligands: transformation from diagnosis (Ga-68) to radionuclide therapy (Lu-177)
Suzuki et al. Reduction of the renal radioactivity of 111In-DOTA-labeled antibody fragments with a linkage cleaved by the renal brush border membrane enzymes
Yang et al. Formulation and preclinical testing of Tc-99m-labeled HYNIC-Glc-FAPT as a FAP-targeting tumor radiotracer
Luo et al. Development of [68Ga] Ga/[177Lu] Lu-DOTA-NI-FAPI-04 containing a nitroimidazole moiety as new FAPI radiotracers with improved tumor uptake and retention
US20250255993A1 (en) Stable radiopharmaceutical compositions and uses thereof
US20240254085A1 (en) Chelators for radiometals and methods of making and using same
EP4291251B1 (en) Her2-binding polypeptide
Lis et al. Development of [99mTc] TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer
JP2024530057A (ja) ネトリン－１検出、コンパニオン検査及び放射線に基づく療法
Bendre Fibroblast activation protein-targeted radioligands for cancer imaging and therapy
EP4696686A1 (en) Fapi theranostic compounds assembled with tetrazine ligation
RU2795398C2 (ru) Комплекс, содержащий нацеливающееся на psma соединение, связанное с радионуклидом свинца или тория
Russelli Development of innovative chelators for the synthesis of 89Zr and [18F] AlF protein-based PET tracers
Fonge Jessica Pougoue Ketchemen1, Fabrice Ngoh Njotu1, 2, Hanan Babeker1, 2, Stephen Ahenkorah3, 4, Anjong Florence Tikum1, Emmanuel Nwangele1, 2, Nikita Henning1, Frederik Cleeren4, and Humphrey Fonge1, 5*. 1Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada
WO2025156030A1 (en) 1,7,13-trioxa-4,10,16-triazacyclooctadecane chelator compositions for radiometals and methods of using same
AU2021361746A1 (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20221122

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260717